Pipamperone

DRUG3 trials

Sponsors

PharmaNeuroBoost N.V., Hannover Medical School

Conditions

Anxiety DisordersChronic SchizophreniaDementiaDepressionMajor Depressive DisorderPsychosomatic DisordersSchizoaffective DisorderSchizophrenia

Phase 2

POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

CompletedNCT01450514

PharmaNeuroBoost N.V.Chronic Schizophrenia, Schizoaffective Disorder

Start: 2012-03-31End: 2012-12-31Updated: 2014-11-19

Phase 3

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

CompletedNCT01312922

PharmaNeuroBoost N.V.Major Depressive Disorder

Start: 2011-09-30End: 2012-12-31Updated: 2022-04-07

Pharmacovigilance in Gerontopsychiatric Patients

TerminatedNCT02374567

Hannover Medical SchoolAnxiety Disorders, Dementia, Depression +2

Start: 2015-01-31End: 2017-06-28Updated: 2018-02-28

Related Papers

Low dose pipamperone therapy for major depression: A randomized controlled clinical trial comparison with citalopram

Personalized Medicine in Psychiatry2024-01-23